プロモーションスケジュール Forte Biosciences, Inc.
詳細なスケジュール
簡易グラフ
会社について Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.| IPO date | 2017-04-13 |
|---|---|
| ISIN | US34962G1094 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.fortebiorx.com |
| Цена ао | 6 |
| 1日あたりの価格変動: | 0% (5.8) |
|---|---|
| 週ごとの価格変動: | -1.86% (5.91) |
| 月ごとの料金変更: | -47.98% (11.15) |
| 3ヶ月間の価格変動: | -69.41% (18.96) |
| 半年間の価格変動: | -18.19% (7.09) |
| 年間の価格変動: | +801.74% (0.6432) |
| 3年間の価格推移: | +326.47% (1.36) |
| 5年間の価格推移: | +966.18% (0.544) |
| 年初からの価格変動: | -68.92% (18.66) |
|
|
過小評価
|
効率
|
|||||||||||||||||||||||||||||||||||||
配当金
|
義務
|
成長の衝動
|
|||||||||||||||||||||||||||||||||||||
| 機関 | 音量 | 共有, % |
|---|---|---|
| Tybourne Capital Management (HK) Limited | 3624548 | 9.96 |
| Perceptive Advisors LLC | 3265359 | 8.97 |
| BVF Inc. | 2982105 | 8.19 |
| Cable Car Capital LLC | 2031987 | 5.58 |
| Fred Alger Management, LLC | 1838965 | 5.05 |
| Farallon Capital Management Llc | 1810455 | 4.97 |
| Bml Capital Management, LLC | 1761702 | 4.84 |
| Vanguard Group Inc | 665230 | 1.83 |
| Geode Capital Management, LLC | 336605 | 0.92 |
| Blackrock Inc. | 182324 | 0.5 |
| スーパーバイザー | 役職 | 支払い | 生年 |
|---|---|---|---|
| Dr. Paul A. Wagner Ph.D. | CEO, President & Chairman | 960.23k | 1970 (55 年) |
| Mr. Christopher Roenfeldt | Chief Operating Officer | N/A | |
| Mr. Steven Ruhl | Chief Technical Officer | N/A | 1957 (68 年) |
| Mr. Antony A. Riley CPA | Chief Financial Officer | 568.48k | 1967 (58 年) |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician & Director | 45k | 1947 (78 年) |
住所: United States, Dallas. TX, 3060 Pegasus Park Drive - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.fortebiorx.com
Webサイト: https://www.fortebiorx.com
